Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMedical Mutual - Ohio Harvoni Coverage Update | Op…
    Ask Trek AI about this page
    CurrentMedical Mutual - OhioPolicy N/A

    Ledipasvir/sofosbuvir (Harvoni) — Coverage and Dosing

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical Mutual - Ohio policy governing prior authorization, dosing, and coverage criteria for ledipasvir/sofosbuvir (Harvoni and authorized generics) for treatment of chronic hepatitis C virus (HCV) in pediatric and adult patients.

    Policy Summary
    PayerMedical Mutual - Ohio
    PolicyLedipasvir/sofosbuvir (Harvoni) — Coverage and Dosing
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateNov 20, 2025
    Last ReviewNov 20, 2025
    Next Review DateNov 20, 2025
    Key ActionObtain prior authorization with prescription by or consultation with a gastroenterologist, hepatologist, infectious diseases physician, or transplant specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥3minimum approved patient age
    12 wkscommon duration
    8 wkspossible short duration
    24 wkspossible extended duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PA
    pharmacy requirement

    Recommended Authorization Criteria

    Chronic HCV — Genotype 1 (authorization durations)

    Approve for the duration noted if the patient meets ALL of the following (A, B, and C):

    A: Age: Patient is ≥ 3 years of age

    B: Treatment and clinical criteria determining duration

    • i (8 weeks): Patient is treatment-naïve; does not have cirrhosis; does not have HIV; is not awaiting liver transplantation; AND baseline HCV RNA < 6 million IU/mLHCV RNA < 6 million IU/mL

      Subcriteria a–e required

    • ii (12 weeks): Patient meets ONE of: (a) treatment-naïve who does not meet Bi (includes treatment-naïve with compensated [Child-Pugh A] cirrhosis regardless of baseline HCV RNA, or treatment-naïve without cirrhosis and baseline HCV RNA ≥ 6 million IU/mL); OR (b) previously treated and does not have cirrhosis; OR (c) decompensated (Child-Pugh B or C) cirrhosis and is ribavirin-eligible (medication prescribed with ribavirin)

      See document for detailed subgroup notes

    • iii (24 weeks): Patient meets ONE of: (a) previously treated with compensated (Child-Pugh A) cirrhosis; OR (b) treatment-naïve or previously treated with decompensated (Child-Pugh B or C) cirrhosis AND is ribavirin-ineligible per prescriber (medication to be prescribed as indicated)

      Prescriber to assess ribavirin ineligibility

    C: Prescriber: Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician

    Chronic HCV — Genotype 4, 5, or 6

    Approve for 12 weeks if ALL of the following are met:

    A: Age: Patient is ≥ 3 years of age
    B: Prescriber: Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician

    Recurrent HCV Post-Liver Transplant — Genotypes 1 or 4

    Approve for 12 weeks if ALL of the following are met:

    A: Age: Patient is ≥ 3 years of age
    B: Post-transplant: Patient has recurrent hepatitis C virus (HCV) after a liver transplantation
    C: Ribavirin: Medication will be prescribed in combination with ribavirin
    D: Prescriber: Prescribed by or in consultation with a prescriber affiliated with a transplant center: gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician

    Other supported uses — selected transplant and renal transplant recipients

    Approvals for select post-transplant and kidney transplant recipients when criteria met:

    Recurrent HCV Post-Liver Transplant Genotypes 5 or 6: Patient is ≥ 18 years of age; AND has recurrent HCV after liver transplantation; AND medication will be prescribed in combination with ribavirin; AND prescribed by or in consultation with a transplant-affiliated specialist (gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician)

    Approve for 12 weeks

    HCV Kidney Transplant Recipients Genotype 1 or 4: Patient is ≥ 18 years of age; AND is a kidney transplant recipient with HCV; AND medication is prescribed by or in consultation with a transplant-affiliated specialist (including nephrologist or renal transplant physician)

    Approve for 12 weeks

    Continuation/Completion of therapy

    Patients already started on ledipasvir/sofosbuvir

    Continuation: Approve remaining duration to complete a course of therapy for indications listed in the Recommended Authorization Criteria (e.g., patient prescribed 12 weeks who has received 3 weeks should be approved for remaining 9 weeks)

    Approve duration described above to complete prescribed course

    Ledipasvir/sofosbuvir is not recommended for use in combination with any other direct-acting antiviral (DAA) regimen that does not include ribavirin. The policy states that ledipasvir/sofosbuvir provides a complete antiviral regimen and should not be combined with other products containing sofosbuvir or additional DAAs for the same course of therapy.

    Treatment with ledipasvir/sofosbuvir is not recommended for pediatric patients younger than 3 years of age because safety and efficacy have not been established in this population.

    Retreatment using ledipasvir/sofosbuvir in patients who have previously received ledipasvir/sofosbuvir (including prior null responders, prior partial responders, prior relapsers, or patients who did not complete a prior course) is not recommended. The policy notes that alternative direct-acting antivirals exist for patients previously treated with ledipasvir/sofosbuvir.

    Coverage is not recommended for circumstances that are not explicitly listed in the Recommended Authorization Criteria. The policy will be updated as new published data become available; only the listed indications and scenarios meet the criteria for approval.

    Initial Authorization Criteria

    Initial therapy criteria

    Initial authorization criteria for ledipasvir/sofosbuvir

    Age: Patient is ≥ 3 years of age for general indications (note: some transplant/renal criteria require ≥ 18 years)
    Dosage duration logic: See genotype- and clinical status-specific nodes: 8, 12, or 24 weeks depending on treatment-naïve status, cirrhosis, prior treatment, transplant status, and ribavirin eligibility

    Detailed subcriteria determine exact duration

    Specialist prescriber: Medication must be prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician (kidney transplant cases may include nephrologist)

    Continuation / Completion Criteria

    Completion of therapy

    Patients already started on ledipasvir/sofosbuvir

    Complete course: Approve remaining duration to complete the prescribed course when initial therapy was for an indication listed in the Recommended Authorization Criteria (example: patient prescribed 12 weeks who has received 3 weeks should be approved for remaining 9 weeks)

    Lab, Diagnostic, and Coding Details

    HCV RNA — Threshold / Value
    HCV RNA threshold< 6 million IU/mL
    Context in duration decisionBaseline HCV RNA < 6 million IU/mL is required for the 8‑week (treatment‑naïve, no cirrhosis) regimen
    Measurement roleUsed as part of the 8‑week approval criteria alongside treatment‑naïve status and absence of cirrhosis

    Prescriber and Prior Authorization Requirements

    Prior Authorization

    Prior authorization and specialist prescriber required

    Prior authorization is recommended for pharmacy benefit coverage of ledipasvir/sofosbuvir. Initial approval requires the medication be prescribed by or in consultation with a physician who specializes in the condition being treated.

    Step Therapy

    Subject to preferred specialty DAA management

    Ledipasvir/sofosbuvir is managed under the Hepatitis C Virus Direct-Acting Antivirals Preferred Specialty Management Policy; step edits or preferred-agent placement among DAAs may apply.

    Documentation Required

    Additional documentation may be requested

    Step Therapy / Placement

    StepRequirement / note
    Subject to Hepatitis C Virus Direct-Acting Antivirals Preferred Specialty Management Policy
    Ledipasvir/sofosbuvir is managed under the payer's preferred specialty management policy for HCV DAAs; placement or step edits among direct-acting antivirals may apply per that policy (prior authorization recommended).

    Key Terms and Definitions

    Ledipasvir/sofosbuvir — Fixed‑dose combination
    Drug compositionFixed‑dose combination of ledipasvir (NS5A inhibitor) and sofosbuvir (nucleotide analog NS5B polymerase inhibitor)
    Indication ageIndicated for treatment of chronic HCV infection in patients ≥ 3 years of age
    FormulationsAvailable as tablets (90 mg/400 mg authorized generic; Harvoni also as 45 mg/200 mg) and oral pellets for pediatric use
    Compensated cirrhosis — Definition and distinction (Child‑Pugh A)
    DefinitionCompensated cirrhosis refers to Child‑Pugh A cirrhosis
    Treatment distinctionDifferent duration/regimen recommendations apply compared with decompensated (Child‑Pugh B or C) cirrhosis

    Background and Indications

    Ledipasvir/sofosbuvir is a fixed-dose combination antiviral that pairs an HCV NS5A inhibitor (ledipasvir) with a NS5B nucleotide polymerase inhibitor (sofosbuvir). It provides a complete oral antiviral regimen for chronic hepatitis C and, per this policy, should be used according to the specified authorization criteria (age thresholds, genotype-specific durations, cirrhosis and transplant considerations).

    Policy Summary
    PayerMedical Mutual - Ohio
    PolicyLedipasvir/sofosbuvir (Harvoni) — Coverage and Dosing
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateNov 20, 2025
    Last ReviewNov 20, 2025
    Next Review DateNov 20, 2025
    Key ActionObtain prior authorization with prescription by or consultation with a gastroenterologist, hepatologist, infectious diseases physician, or transplant specialist.
    SourceLink
    On This Page
    Recommended Authorization CriteriaInitial Authorization CriteriaContinuation / Completion CriteriaLab, Diagnostic, and Coding DetailsPrescriber and Prior Authorization RequirementsStep Therapy / PlacementKey Terms and DefinitionsBackground and Indications

    The Company may request additional documentation to support medical necessity and coverage determinations; providers must make requested materials available.

    • Documentation may include patient records, relevant test results, and credentials of the provider ordering or performing the service.
    • Provide requested documentation promptly to avoid delays in coverage determination.
    Denial Risk

    Denial triggers and reimbursement risks

    The Company may deny reimbursement when the drug or services are not medically necessary, are investigational/experimental, are outside the member's benefits, or when inappropriate or excessive billing patterns are identified.

    • Denial may follow if requested documentation does not support medical necessity.
    • Services outside the scope of member benefits or experimental uses are denial triggers.
    • Patterns of inappropriate or excessive billing may result in denial.
    Example policy implicationPatients with compensated (Child‑Pugh A) cirrhosis may receive 12 weeks (treatment‑naïve) or 24 weeks if previously treated, per genotype‑specific guidance